Literature DB >> 3774700

Vasodilator therapy of dilated cardiomyopathy.

J N Cohn.   

Abstract

Vasoconstriction increases impedance to ventricular ejection and impairs the performance of the dilated myopathic heart. Vasodilator drug therapy by reducing vascular resistance, increasing vascular compliance and increasing vascular capacitance improves cardiac function and relieves the signs and symptoms of congestive heart failure. Earlier intervention in an attempt to alter the natural history of cardiomyopathy should be studied.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3774700      PMCID: PMC2418788          DOI: 10.1136/pgmj.62.728.599

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

1.  Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus.

Authors:  K Chatterjee; W W Parmley; H J Swan; G Berman; J Forrester; H S Marcus
Journal:  Circulation       Date:  1973-10       Impact factor: 29.690

2.  Treatment of refractory heart failure with infusion of nitroprusside.

Authors:  N H Guiha; J N Cohn; E Mikulic; J A Franciosa; C J Limas
Journal:  N Engl J Med       Date:  1974-09-19       Impact factor: 91.245

3.  Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance.

Authors:  J N Cohn
Journal:  Circulation       Date:  1973-07       Impact factor: 29.690

4.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

Authors:  T B Levine; G S Francis; S R Goldsmith; A B Simon; J N Cohn
Journal:  Am J Cardiol       Date:  1982-05       Impact factor: 2.778

5.  Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure.

Authors:  T B Levine; J A Franciosa; J N Cohn
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

6.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.

Authors:  J N Cohn; T B Levine; M T Olivari; V Garberg; D Lura; G S Francis; A B Simon; T Rector
Journal:  N Engl J Med       Date:  1984-09-27       Impact factor: 91.245

7.  Nitrate therapy for congestive heart failure.

Authors:  J A Franciosa; L A Nordstrom; J N Cohn
Journal:  JAMA       Date:  1978-08-04       Impact factor: 56.272

8.  Regional blood flow response to orthostasis in patients with congestive heart failure.

Authors:  S R Goldsmith; G S Francis; T B Levine; J N Cohn
Journal:  J Am Coll Cardiol       Date:  1983-06       Impact factor: 24.094

9.  Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure.

Authors:  C Curtiss; J N Cohn; T Vrobel; J A Franciosa
Journal:  Circulation       Date:  1978-11       Impact factor: 29.690

  9 in total
  1 in total

Review 1.  Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.

Authors:  J P Mulrow; M H Crawford
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.